Please wait

Exhibit 107

CALCULATION OF FILING FEE TABLES

FORM S-3

(Form Type)

Madrigal Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
    

Security

Type

  

Security

Class

Title

  

Fee

Calculation

or Carry

Forward

Rule (1)

  

Amount

Registered (2)

  

Proposed

Maximum

Offering

Price Per

Unit (2)

  

Maximum

Aggregate

Offering

Price (2)

  

Fee

Rate
(1)

  

Amount of

Registration

Fee (1)

   Carry
Forward
Form
Type		  

Carry
Forward

File
Number

   Carry
Forward
Initial
Effective
Date		   Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to
be Carried
Forward
 
Newly Registered Securities
                         

Fees to Be

Paid

   Debt   Debt Securities  

Rule 456(b) and

Rule 457(r)

                    
  Equity  

Preferred Stock, $0.0001 par

value per share

  

Rule 456(b) and

Rule 457(r)

                                    
  Equity  

Common Stock, $0.0001 par

value per share

  

Rule 456(b) and

Rule 457(r)

                                    
  Other   Warrants  

Rule 456(b) and

Rule 457(r)

                                    
  Other   Units  

Rule 456(b) and

Rule 457(r)

                                    
                         

Fees

Previously

Paid

   N/A   N/A   N/A   N/A   N/A   N/A   N/A   N/A          
 
Carry Forward Securities(3)
                         

Carry

Forward

Securities

   Equity  

Common Stock, $0.0001 par

value per share

   415(a)(6)   $174,825,893   N/A   $174,825,893       424(b)(5)   333-56666   May 9, 2023   $19,266
                         

Carry

Forward

Securities

   Equity  

Common Stock, $0.0001 par

value per share

   415(a)(6)   3,914,910   $186.10   $731,305,188       424(b)(3)   333-56666   August 8, 2023   $80,590
                   
    Total Offering Amounts      $906,131,081     N/A          
                   
    Total Fees Previously Paid          N/A          
                   
    Total Fee Offsets          N/A          
                   
    Net Fee Due                $0                

 

(1)

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Madrigal Pharmaceuticals, Inc. (the “Company”) is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a “pay as you go” basis. The Company will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

(2)

An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. Separate consideration may or may not be received for securities that are issuable upon exercise, conversion or exchange of other securities. Pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of the Company’s securities that become issuable by reason of any stock splits, stock dividend or similar transaction.

(3)

In accordance with Rule 415(a)(6) of the Securities Act, this Registration Statement carries forward $174,825,893 and $731,305,188 of unsold securities previously registered under the Company’s former Registration Statement on Form S-3 (File No. 333-256666) and related prospectus supplements dated May 9, 2023 and August 8, 2023, respectively (the “Prior Prospectuses”). In connection with the registration of such unsold securities on the Prior Prospectuses, the Registrant paid registration fees of $19,266 and $80,590, respectively, which are being carried forward to this Registration Statement. Pursuant to Rule 415(a)(6), the offerings of the unsold securities registered under the Prior Prospectuses are deemed terminated as of the date of effectiveness of this Registration Statement.